SubsidieMeestersRepurposing a human drug to treat Alzheimer’s disease
This project aims to validate an approved drug that inhibits tau accumulation in Alzheimer's, advancing it towards commercialization as a novel treatment for the disease.
Projectdetails
Introduction
Alzheimer’s disease is a major cause of disability among older adults and represents substantial financial and human costs to patients, families, and societies worldwide. Currently, there is no cure for Alzheimer’s disease.
Need for Novel Treatments
Thus, novel effective treatments need to be developed that target the root causes of Alzheimer’s disease, in particular the pathogenic accumulation of the protein tau.
Breakthrough Achievements
During our ERC project, we achieved a breakthrough by demonstrating that an approved human drug efficiently inhibits pathogenic tau accumulation in several pre-clinical assays.
Drug Characteristics
The identified FDA/EMA-approved small molecule has several important characteristics:
- It is orally bioavailable.
- It is safe in humans.
- It reaches the brain at high concentrations.
Project Aim
It is the aim of this proof of concept project to provide further pre-clinical validation of the drug and to pursue the needed steps towards IPR protection and commercialization.
Potential Impact
Because no disease-modifying therapy currently exists for Alzheimer's disease, bringing the novel repurposed drug closer to the market promises an outstanding high gain.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 150.000 |
| Totale projectbegroting | € 150.000 |
Tijdlijn
| Startdatum | 1-6-2022 |
| Einddatum | 30-11-2023 |
| Subsidiejaar | 2022 |
Partners & Locaties
Projectpartners
- DEUTSCHES ZENTRUM FUR NEURODEGENERATIVE ERKRANKUNGEN EVpenvoerder
Land(en)
Geen landeninformatie beschikbaar
Vergelijkbare projecten binnen European Research Council
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
MANUNKIND: Determinants and Dynamics of Collaborative ExploitationThis project aims to develop a game theoretic framework to analyze the psychological and strategic dynamics of collaborative exploitation, informing policies to combat modern slavery. | ERC STG | € 1.497.749 | 2022 | Details |
Elucidating the phenotypic convergence of proliferation reduction under growth-induced pressureThe UnderPressure project aims to investigate how mechanical constraints from 3D crowding affect cell proliferation and signaling in various organisms, with potential applications in reducing cancer chemoresistance. | ERC STG | € 1.498.280 | 2022 | Details |
Uncovering the mechanisms of action of an antiviral bacteriumThis project aims to uncover the mechanisms behind Wolbachia's antiviral protection in insects and develop tools for studying symbiont gene function. | ERC STG | € 1.500.000 | 2023 | Details |
The Ethics of Loneliness and SociabilityThis project aims to develop a normative theory of loneliness by analyzing ethical responsibilities of individuals and societies to prevent and alleviate loneliness, establishing a new philosophical sub-field. | ERC STG | € 1.025.860 | 2023 | Details |
MANUNKIND: Determinants and Dynamics of Collaborative Exploitation
This project aims to develop a game theoretic framework to analyze the psychological and strategic dynamics of collaborative exploitation, informing policies to combat modern slavery.
Elucidating the phenotypic convergence of proliferation reduction under growth-induced pressure
The UnderPressure project aims to investigate how mechanical constraints from 3D crowding affect cell proliferation and signaling in various organisms, with potential applications in reducing cancer chemoresistance.
Uncovering the mechanisms of action of an antiviral bacterium
This project aims to uncover the mechanisms behind Wolbachia's antiviral protection in insects and develop tools for studying symbiont gene function.
The Ethics of Loneliness and Sociability
This project aims to develop a normative theory of loneliness by analyzing ethical responsibilities of individuals and societies to prevent and alleviate loneliness, establishing a new philosophical sub-field.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Synaptic resilience in Tau-induced neurodegenerationThis project aims to uncover the mechanisms of synaptic remodeling during hibernation to develop therapies that reverse Tau-induced synaptic decline in dementia. | ERC ADG | € 2.500.000 | 2023 | Details |
Novel biomarkers for improving diagnostics, prognostics, and treatments of Alzheimer’s diseaseADVANCE-AD aims to enhance Alzheimer's diagnostics and treatment by developing cost-effective blood-based biomarkers and algorithms for early detection and intervention in pre-symptomatic patients. | ERC ADG | € 2.500.000 | 2024 | Details |
Deciphering Alzheimer’s disease molecular subtypes to advance treatment development.This project aims to identify Alzheimer's disease subtypes through CSF proteomics to develop tailored treatments and theragnostic tools linked to cognitive decline and genetic factors. | ERC COG | € 2.999.934 | 2025 | Details |
Dementia/Alzheimer Drug Attributed to Cystatin-C and other mutations – precision medicine drug developmentATI's AT-001 aims to stop and revert dementia by preventing protein aggregation, with promising Phase IIa results leading to upcoming registration trials and POC studies for commercialization. | EIC Accelerator | € 2.500.000 | 2023 | Details |
Synaptic resilience in Tau-induced neurodegeneration
This project aims to uncover the mechanisms of synaptic remodeling during hibernation to develop therapies that reverse Tau-induced synaptic decline in dementia.
Novel biomarkers for improving diagnostics, prognostics, and treatments of Alzheimer’s disease
ADVANCE-AD aims to enhance Alzheimer's diagnostics and treatment by developing cost-effective blood-based biomarkers and algorithms for early detection and intervention in pre-symptomatic patients.
Deciphering Alzheimer’s disease molecular subtypes to advance treatment development.
This project aims to identify Alzheimer's disease subtypes through CSF proteomics to develop tailored treatments and theragnostic tools linked to cognitive decline and genetic factors.
Dementia/Alzheimer Drug Attributed to Cystatin-C and other mutations – precision medicine drug development
ATI's AT-001 aims to stop and revert dementia by preventing protein aggregation, with promising Phase IIa results leading to upcoming registration trials and POC studies for commercialization.